20-hydroxyeicosatetraeonic acid: A new target for the treatment of hypertension

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 4, 2010, Pages 336-344

  Williams, Jan M ^a   Murphy, Sydney ^a   Burke, Marilyn ^a   Roman, Richard J ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

20 HETE; blood vessels; hypertension; kidney; vascular tone

Indexed keywords

17 OCTADECYNOIC ACID; 20 HYDROXYICOSA DIENOIC ACID; 20 HYDROXYICOSA DIENOYL GLYCINE; 20 HYDROXYICOSATETRAENOIC ACID; 20 HYDROXYICOSATETRAENOIC ACID BLOCKING AGENT; 20 HYDROXYICOSATETRAENOIC ACID STIMULATING AGENT; ANDROGEN; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; ARACHIDONIC ACID; CYTOCHROME; CYTOCHROME P450 4A11; CYTOCHROME P450 4F2; DEOXYCORTICOSTERONE ACETATE; DIBROMODODEC 11 ENOIC ACID; HET 0016; N (3 CHLORO 4 MORPHOLIN 4 YL)PHENYL N' HYDROXYIMIDO FORMAMIDE; N HYROXY N' (4 BUTYL 2 METHYLPHENYL)FORMAMIDINE; N METHYLSULFONYL 12,12 DIBROMODODEC 11 ENAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; SODIUM ION; TRANSFORMING GROWTH FACTOR BETA; TS 011; UNCLASSIFIED DRUG;

BLOOD VESSEL TONE; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; FATTY ACID METABOLISM; FATTY ACID SYNTHESIS; GENETIC VARIABILITY; HUMAN; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM RETENTION; SODIUM TRANSPORT; VASCULAR RESISTANCE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARACHIDONIC ACID; BIOLOGICAL TRANSPORT; BLOOD VESSELS; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; HYPERTENSION; KIDNEY; MOLECULAR TARGETED THERAPY; SODIUM;

EID: 77958461840     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181f04b1c     Document Type: Review

References (177)

1. Joffres MR, Hamet P, MacLean DR, et al. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens. 2001;14:1099-1105.
2. Ito O, Nakamura Y, Tan L, et al. Expression of cytochrome P-450 4 enzymes in the kidney and liver: regulation by PPAR and species-difference between rat and human. Mol Cell Biochem. 2006;284: 141-148.
3. Antoun J, Goulitquer S, Amet Y, et al. CYP4F3B is induced by PGA1 in human liver cells: a regulation of the 20-HETE synthesis. J Lipid Res. 2008;49:2135-2141.
4. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension. 1998;31:225-231.
5. Ito O, Alonso-Galicia M, Hopp KA, et al. Localization of cytochrome P-450 4A isoforms along the rat nephron. Am J Physiol. 1998;274:F395-F404.
6. Ito O, Roman RJ. Regulation of P-450 4A activity in the glomerulus of the rat. Am J Physiol. 1999;276:R1749-R1757.
7. Omata K, Abraham NG, Schwartzman ML. Renal cytochrome P-450-arachidonic acid metabolism: localization and hormonal regulation in SHR. Am J Physiol. 1992;262:F591-F599.
8. Carroll MA, Sala A, Dunn CE, et al. Structural identification of cytochrome P450-dependent arachidonate metabolites formed by rabbit medullary thick ascending limb cells. J Biol Chem. 1991;266: 12306-12312.
9. Escalante B, Erlij D, Falck JR, et al. Effect of cytochrome P450 arachidonate metabolites on ion transport in rabbit kidney loop of Henle. Science. 1991;251:799-802.
10. Ito O, Roman RJ. Role of 20-HETE in elevating chloride transport in the thick ascending limb of Dahl SS/Jr rats. Hypertension. 1999;33: 419-423.
11. Yousif MH, Benter IF, Roman RJ. Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury. Auton Autacoid Pharmacol. 2009;29:33-41.
12. Zordoky BN, Anwar-Mohamed A, Aboutabl ME, et al. Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol Appl Pharmacol. 2010; 242:38-46.
13. Birks EK, Bousamra M, Presberg K, et al. Human pulmonary arteries dilate to 20-HETE, an endogenous eicosanoid of lung tissue. Am J Physiol. 1997;272:L823-L829.
14. Knickle LC, Bend JR. Bioactivation of arachidonic acid by the cytochrome P450 monooxygenases of guinea pig lung: the orthologue of cytochrome P450 2B4 is solely responsible for formation of epoxyeicosatrienoic acids. Mol Pharmacol. 1994;45:1273-1280.
15. Zhu D, Birks EK, Dawson CA, et al. Hypoxic pulmonary vasocon-striction is modified by P-450 metabolites. Am J Physiol Heart Circ Physiol. 2000;279:H1526-H1533.
16. Zhu D, Effros RM, Harder DR, et al. Tissue sources of cytochrome P450 4A and 20-HETE synthesis in rabbit lungs. Am J Respir Cell Mol Biol. 1998;19:121-128.
17. Gebremedhin D, Lange AR, Lowry TF, et al. Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res. 2000;87: 60-65.
18. Harder DR, Gebremedhin D, Narayanan J, et al. Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. Am J Physiol. 1994;266:H2098-H2107.
19. Renic M, Klaus JA, Omura T, et al. Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab. 2009;29:629-639.
20. Carroll MA, Kemp R, Cheng MK, et al. Regulation of preglomerular microvascular 20-hydroxyeicosatetraenoic acid levels by salt depletion. Med Sci Monit. 2001;7:567-572.
21. Croft KD, McGiff JC, Sanchez-Mendoza A, et al. Angiotensin II releases 20-HETE from rat renal microvessels. Am J Physiol Renal Physiol. 2000; 279:F544-F551.
22. Imig JD, Zou AP, Stec DE, et al. Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am J Physiol. 1996;270:R217-R227.
23. Sun CW, Alonso-Galicia M, Taheri MR, et al. Nitric oxide-20- hydroxyeicosatetraenoic acid interaction in the regulation of K+ channel activity and vascular tone in renal arterioles. Circ Res. 1998;83:1069-1079.
24. Lasker JM, Chen WB, Wolf I, et al. Formation of 20-hydroxyeico- satetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem. 2000;275:4118-4126.
25. Powell PK, Wolf I, Jin R, et al. Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Ther. 1998;285:1327-1336.
26. Christmas P, Jones JP, Patten CJ, et al. Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J Biol Chem. 2001;276:38166-38172.
27. Sundseth SS, Waxman DJ. Sex-dependent expression and clofibrate inducibility of cytochrome P450 4A fatty acid omega-hydroxylases. Male specificity of liver and kidney CYP4A2 mRNA and tissue-specific regulation by growth hormone and testosterone. J Biol Chem. 1992;267: 3915-3921.
28. Vera T, Taylor M, Bohman Q, et al. Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. Hypertension. 2005; 45:730-735.
29. Zhou Y, Huang H, Chang HH, et al. Induction of renal 20- hydroxyeicosatetraenoic acid by clofibrate attenuates high-fat diet-induced hypertension in rats. J Pharmacol Exp Ther. 2006;317:11-18.
30. Imaoka S, Shimojo N, Funae Y. Induction of renal cytochrome P-450 in hepatic microsomes of diabetic rats. Biochem Biophys Res Commun. 1988;152:680-687.
31. Kroetz DL, Yook P, Costet P, et al. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem. 1998;273:31581-31589.
32. Catella F, Lawson JA, Fitzgerald DJ, et al. Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci USA. 1990;87: 5893-5897.
33. Sacerdoti D, Balazy M, Angeli P, et al. Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE. J Clin Invest. 1997;100: 1264-1270.
34. Holla VR, Adas F, Imig JD, et al. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci USA. 2001;98:5211-5216.
35. Honeck H, Gross V, Erdmann B, et al. Cytochrome P450-dependent renal arachidonic acid metabolism in desoxycorticosterone acetate-salt hypertensive mice. Hypertension. 2000;36:610-616.
36. Imig JD, Falck JR, Gebremedhin D, et al. Elevated renovascular tone in young spontaneously hypertensive rats. Role of cytochrome P-450. Hypertension. 1993;22:357-364.
37. Kroetz DL, Huse LM, Thuresson A, et al. Developmentally regulated expression of the CYP4A genes in the spontaneously hypertensive rat kidney. Mol Pharmacol. 1997;52:362-372.
38. Laffer CL, Laniado-Schwartzman M, Wang MH, et al. 20-HETE and furosemide-induced natriuresis in salt-sensitive essential hypertension. Hypertension. 2003;41:703-708.
39. Ma YH, Schwartzman ML, Roman RJ. Altered renal P-450 metabolism of arachidonic acid in Dahl salt-sensitive rats. Am J Physiol. 1994;267: R579-R589.
40. Messer-Letienne I, Bernard N, Roman RJ, et al. 20-Hydroxyeicosate- traenoic acid and renal function in Lyon hypertensive rats. Eur J Pharmacol. 1999;378:291-297.
41. Muthalif MM, Benter IF, Karzoun N, et al. 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci USA. 1998;95:12701-12706.
42. Sacerdoti D, Abraham NG, McGiff JC, et al. Renal cytochrome P-450-dependent metabolism of arachidonic acid in spontaneously hypertensive rats. Biochem Pharmacol. 1988;37:521-527.
43. Stec DE, Deng AY, Rapp JP, et al. Cytochrome P4504A genotype cosegregates with hypertension in Dahl S rats. Hypertension. 1996;27: 564-568.
44. Nakagawa K, Marji JS, Schwartzman ML, et al. Androgen-mediated induction of the kidney arachidonate hydroxylases is associated with the development of hypertension. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1055-R1062.
45. Singh H, Cheng J, Deng H, et al. Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension. 2007;50:123-129.
46. Singh H, Schwartzman ML. Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol Rep. 2008; 60:29-37.
47. Williams JM, Sarkis A, Hoagland KM, et al. Transfer of the CYP4A region of chromosome 5 from Lewis to Dahl S rats attenuates renal injury. Am J Physiol Renal Physiol. 2008;295:F1764-F1777.
48. Roman RJ, Hoagland KM, Lopez B, et al. Characterization of blood pressure and renal function in chromosome 5 congenic strains of Dahl S rats. Am J Physiol Renal Physiol. 2006;290:F1463-F1471.
49. Oyekan AO, Youseff T, Fulton D, et al. Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J Clin Invest. 1999;104: 1131-1137.
50. Carroll MA, Louzan M, McGiff JC. K+ alters cytochrome P-450-dependent arachidonate metabolism by rabbit renomedullary cells. Am J Physiol. 1990;258:F1084-F1089.
51. Wang W, Lu M. Effect of arachidonic acid on activity of the apical K+ channel in the thick ascending limb of the rat kidney. J Gen Physiol. 1995;106:727-743.
52. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:131-185.
53. Carroll MA, Garcia MP, Falck JR, et al. Cyclooxygenase dependency of the renovascular actions of cytochrome P450-derived arachidonate metabolites. J Pharmacol Exp Ther. 1992;260:104-109.
54. Collins XH, Harmon SD, Kaduce TL, et al. Omega-oxidation of 20-hydroxyeicosatetraenoic acid (20-HETE) in cerebral microvascular smooth muscle and endothelium by alcohol dehydrogenase 4. J Biol Chem. 2005;280:33157-33164.
55. Kaduce TL, Fang X, Harmon SD, et al. 20-hydroxyeicosatetraenoic acid (20-HETE) metabolism in coronary endothelial cells. J Biol Chem. 2004; 279:2648-2656.
56. Escalante B, Omata K, Sessa W, et al. 20-hydroxyeicosatetraenoic acid is an endothelium-dependent vasoconstrictor in rabbit arteries. Eur J Pharmacol. 1993;235:1-7.
57. Schwartzman ML, Falck JR, Yadagiri P, et al. Metabolism of 20-hydroxyeicosatetraenoic acid by cyclooxygenase. Formation and identification of novel endothelium-dependent vasoconstrictor metabolites. J Biol Chem. 1989;264:11658-11662.
58. Ma YH, Gebremedhin D, Schwartzman ML, et al. 20-Hydroxyeicosate-traenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. Circ Res. 1993;72:126-136.
59. Zou AP, Fleming JT, Falck JR, et al. 20-HETE is an endogenous inhibitor of the large-conductance Ca(2+)-activated K+ channel in renal arterioles. Am J Physiol. 1996;270:R228-R237.
60. Lange A, Gebremedhin D, Narayanan J, et al. 20-Hydroxyeicosate-traenoic acid-induced vasoconstriction and inhibition of potassium current in cerebral vascular smooth muscle is dependent on activation of protein kinase C. J Biol Chem. 1997;272:27345-27352.
61. Nowicki S, Chen SL, Aizman O, et al. 20-Hydroxyeicosa-tetraenoic acid (20 HETE) activates protein kinase C. Role in regulation of rat renal Na+, K+-ATPase. J Clin Invest. 1997;99:1224-1230.
62. Obara K, Koide M, Nakayama K. 20-Hydroxyeicosatetraenoic acid potentiates stretch-induced contraction of canine basilar artery via PKC alpha-mediated inhibition of KCa channel. Br J Pharmacol. 2002;137:1362-1370.
63. Sun CW, Falck JR, Harder DR, et al. Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension. 1999;33:414-418.
64. Muthalif MM, Benter IF, Khandekar Z, et al. Contribution of Ras GTPase/MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt- induced hypertension. Hypertension. 2000; 35:457-463.
65. Muthalif MM, Uddin MR, Fatima S, et al. Small GTP binding protein Ras contributes to norepinephrine-induced mitogenesis of vascular smooth muscle cells. Prostaglandins Other Lipid Mediat. 2001;65: 33-43.
66. Randriamboavonjy V, Busse R, Fleming I. 20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-kinase. Hypertension. 2003;41:801-806.
67. Gebremedhin D, Lange AR, Narayanan J, et al. Cat cerebral arterial smooth muscle cells express cytochrome P450 4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-type Ca2+ current. J Physiol. 1998;507:771-781.
68. Basora N, Boulay G, Bilodeau L, et al.20-hydroxyeicosatetraenoic acid (20-HETE) activates mouse TRPC6 channels expressed in HEK293 cells. J Biol Chem. 2003;278:31709-31716.
69. Brayden JE, Earley S, Nelson MT, et al. Transient receptor potential (TRP) channels, vascular tone and autoregulation of cerebral blood flow. Clin Exp Pharmacol Physiol. 2008;35:1116-1120.
70. Kauser K, Clark JE, Masters BS, et al. Inhibitors of cytochrome P-450 attenuate the myogenic response of dog renal arcuate arteries. Circ Res. 1991;68:1154-1163.
71. Zou AP, Imig JD, Kaldunski M, et al. Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. Am J Physiol. 1994;266:F275-F282.
72. Carroll MA, Balazy M, Margiotta P, et al. Cytochrome P-450-dependent HETEs: profile of biological activity and stimulation by vasoactive peptides. Am J Physiol. 1996;271:R863-R869.
73. Oyekan A, Balazy M, McGiff JC. Renal oxygenases: differential contribution to vasoconstriction induced by ET-1 and ANG II. Am J Physiol. 1997;273:R293-R300.
74. Oyekan AO, McGiff JC. Cytochrome P-450-derived eicosanoids participate in the renal functional effects of ET-1 in the anesthetized rat. Am J Physiol. 1998;274:R52-R61.
75. Cambj-Sapunar L, Yu M, Harder DR, et al. Contribution of 5-hydroxytryptamine1B receptors and 20-hydroxyeiscosatetraenoic acid to fall in cerebral blood flow after subarachnoid hemorrhage. Stroke. 2003;34:1269-1275.
76. Alonso-Galicia M, Maier KG, Greene AS, et al. Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am J Physiol Regul Integr Comp Physiol. 2002;283: R60-R68.
77. Hercule HC, Oyekan AO. Role of NO and cytochrome P-450-derived eicosanoids in ET-1-induced changes in intrarenal hemodynamics in rats. Am J Physiol Regul Integr Comp Physiol. 2000;279:R2132-R2141.
78. Imig JD, Pham BT, LeBlanc EA, et al. Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. Hypertension. 2000;35:307-312.
79. Vazquez B, Rios A, Escalante B. Arachidonic acid metabolism modulates vasopressin-induced renal vasoconstriction. Life Sci. 1995;56: 1455-1466.
80. Alonso-Galicia M, Drummond HA, Reddy KK, et al. Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension. 1997;29:320-325.
81. Alonso-Galicia M, Hudetz AG, Shen H, et al. Contribution of 20-HETE to vasodilator actions of nitric oxide in the cerebral microcirculation. Stroke. 1999;30:2727-2734; discussion 2734.
82. Lopez B, Moreno C, Salom MG, et al. Role of guanylyl cyclase and cytochrome P-450 on renal response to nitric oxide. Am J Physiol Renal Physiol. 2001;281:F420-F427.
83. Oyekan AO, McGiff JC. Functional response of the rat kidney to inhibition of nitric oxide synthesis: role of cytochrome p450-derived arachidonate metabolites. Br J Pharmacol. 1998;125:1065-1073.
84. Botros FT, Laniado-Schwartzman M, Abraham NG. Regulation of cyclooxygenase-and cytochrome p450-derived eicosanoids by heme oxygenase in the rat kidney. Hypertension. 2002;39:639-644.
85. Coceani F, Kelsey L, Seidlitz E, et al. Inhibition of the contraction of the ductus arteriosus to oxygen by 1-aminobenzotriazole, a mechanism-based inactivator of cytochrome P450. Br J Pharmacol. 1996;117: 1586-1592.
86. Hoagland KM, Maier KG, Roman RJ. Contributions of 20-HETE to the antihypertensive effects of Tempol in Dahl salt-sensitive rats. Hypertension. 2003;41:697-702.
87. Alonso-Galicia M, Sun CW, Falck JR, et al. Contribution of 20-HETE to the vasodilator actions of nitric oxide in renal arteries. Am J Physiol. 1998;275:F370-F378.
88. Cheng J, Ou JS, Singh H, et al. 20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am J Physiol Heart Circ Physiol. 2008;294:H1018-H1026.
89. Cheng J, Wu CC, Gotlinger KH, et al. 20-hydroxy-5,8,11,14- eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling. J Pharmacol Exp Ther. 2010;332:57-65.
90. Wang JS, Singh H, Zhang F, et al. Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ Res. 2006;98:962-969.
91. Zou AP, Imig JD, Ortiz de Montellano PR, et al. Effect of P-450 omega-hydroxylase metabolites of arachidonic acid on tubuloglomerular feedback. Am J Physiol. 1994;266:F934-F941.
92. Zhao X, Inscho EW, Bondlela M, et al. The CYP450 hydroxylase pathway contributes to P2X receptor-mediated afferent arteriolar vasoconstriction. Am J Physiol Heart Circ Physiol. 2001;281:H2089-H2096.
93. Quigley R, Baum M, Reddy KM, et al. Effects of 20-HETE and 19(S)-HETE on rabbit proximal straight tubule volume transport. Am J Physiol Renal Physiol. 2000;278:F949-F953.
94. Ominato M, Satoh T, Katz AI. Regulation of Na-K-ATPase activity in the proximal tubule: role of the protein kinase C pathway and of eicosanoids. J Membr Biol. 1996;152:235-243.
95. Schwartzman M, Ferreri NR, Carroll MA, et al. Renal cytochrome P450-related arachidonate metabolite inhibits (Na+ + K+)ATPase. Nature. 1985;314:620-622.
96. Ribeiro CM, Dubay GR, Falck JR, et al. Parathyroid hormone inhibits Na(+)-K(+)-ATPase through a cytochrome P-450 pathway. Am J Physiol. 1994;266:F497-F505.
97. Satoh T, Cohen HT, Katz AI. Intracellular signaling in the regulation of renal Na-K-ATPase. I. Role of cyclic AMP and phospholipase A2. J Clin Invest. 1992;89:1496-1500.
98. Silverstein DM, Barac-Nieto M, Falck JR, et al. 20-HETE mediates the effect of parathyroid hormone and protein kinase C on renal phosphate transport. Prostaglandins Leukot Essent Fatty Acids. 1998;58:209-213.
99. Escalante BA, McGiff JC, Oyekan AO. Role of cytochrome P-450 arachidonate metabolites in endothelin signaling in rat proximal tubule. Am J Physiol Renal Physiol. 2002;282:F144-F150.
100. Carroll MA, Balazy M, Huang DD, et al. Cytochrome P450-derived renal HETEs: storage and release. Kidney Int. 1997;51:1696-1702.
101. Sanchez-Mendoza A, Lopez-Sanchez P, Vazquez-Cruz B, et al. Angiotensin II modulates ion transport in rat proximal tubules through CYP metabolites. Biochem Biophys Res Commun. 2000;272:423-430.
102. Zou AP, Drummond HA, Roman RJ. Role of 20-HETE in elevating loop chloride reabsorption in Dahl SS/Jr rats. Hypertension. 1996;27:631-635.
103. Yu M, Lopez B, Dos Santos EA, et al. Effects of 20-HETE on Na+ transport and Na+-K+-ATPase activity in the thick ascending loop of Henle. Am J Physiol Regul Integr Comp Physiol. 2007;292:R2400-R2405.
104. Amlal H, LeGoff C, Vernimmen C, et al. ANG II controls Na(+)-K+(NH4+)-2Cl-cotransport via 20-HETE and PKC in medullary thick ascending limb. Am J Physiol. 1998;274:C1047-C1056.
105. Lu M, Zhu Y, Balazy M, et al. Effect of angiotensin II on the apical K+ channel in the thick ascending limb of the rat kidney. J Gen Physiol. 1996;108:537-547.
106. Grider JS, Falcone JC, Kilpatrick EL, et al. P450 arachidonate metabolites mediate bradykinin-dependent inhibition of NaCl transport in the rat thick ascending limb. Can J Physiol Pharmacol. 1997;75:91-96.
107. Amlal H, Legoff C, Vernimmen C, et al. Na(+)-K+(NH4+)-2Cl-cotransport in medullary thick ascending limb: control by PKA, PKC, and 20-HETE. Am J Physiol. 1996;271:C455-C463.
108. Wang W, Lu M, Balazy M, et al. Phospholipase A2 is involved in mediating the effect of extracellular Ca2+ on apical K+ channels in rat TAL. Am J Physiol. 1997;273:F421-F429.
109. Wang WH, Lu M, Hebert SC. Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL. Am J Physiol. 1996;271:C103-C111.
110. Lu M, Wang X, Wang W. Nitric oxide increases the activity of the apical 70-pS K+ channel in TAL of rat kidney. Am J Physiol. 1998;274: F946-F950.
111. Liu H, Mount DB, Nasjletti A, et al. Carbon monoxide stimulates the apical 70-pS K+ channel of the rat thick ascending limb. J Clin Invest. 1999;103:963-970.
112. Cowley AW Jr, Roman RJ. The role of the kidney in hypertension. JAMA. 1996;275:1581-1589.
113. Roman RJ, Kaldunski M. Pressure natriuresis and cortical and papillary blood flow in inbred Dahl rats. Am J Physiol. 1991;261:R595-R602.
114. Roman RJ, Cowley AW Jr, Garcia-Estan J, et al. Pressure-diuresis in volume-expanded rats. Cortical and medullary hemodynamics. Hypertension. 1988;12:168-176.
115. Mattson DL, Lu S, Roman RJ, et al. Relationship between renal perfusion pressure and blood flow in different regions of the kidney. Am J Physiol. 1993;264:R578-R583.
116. Garcia-Estan J, Roman RJ. Role of renal interstitial hydrostatic pressure in the pressure diuresis response. Am J Physiol. 1989;256:F63-F70.
117. Williams JM, Sarkis A, Lopez B, et al. Elevations in renal interstitial hydrostatic pressure and 20-hydroxyeicosatetraenoic acid contribute to pressure natriuresis. Hypertension. 2007;49:687-694.
118. Granger JP. Pressure natriuresis. Role of renal interstitial hydrostatic pressure. Hypertension. 1992;19:I9-I17.
119. Khraibi AA, Knox FG. Effect of renal decapsulation on renal interstitial hydrostatic pressure and natriuresis. Am J Physiol. 1989;257:R44-R48.
120. Khraibi AA, Haas JA, Knox FG. Effect of renal perfusion pressure on renal interstitial hydrostatic pressure in rats. Am J Physiol. 1989;256: F165-F170.
121. Haas JA, Granger JP, Knox FG. Effect of renal perfusion pressure on sodium reabsorption from proximal tubules of superficial and deep nephrons. Am J Physiol. 1986;250:F425-F429.
122. Kinoshita Y, Knox FG. Role of prostaglandins in proximal tubule sodium reabsorption: response to elevated renal interstitial hydrostatic pressure. Circ Res. 1989;64:1013-1018.
123. Roman RJ. Pressure-diuresis in volume-expanded rats. Tubular reabsorption in superficial and deep nephrons. Hypertension. 1988;12:177-183.
124. Magyar CE, Zhang Y, Holstein-Rathlou NH, et al. Proximal tubule Na transporter responses are the same during acute and chronic hypertension. Am J Physiol Renal Physiol. 2000;279:F358-F369.
125. Zhang Y, Magyar CE, Norian JM, et al. Reversible effects of acute hypertension on proximal tubule sodium transporters. Am J Physiol. 1998;274:C1090-C1100.
126. Zhang Y, Mircheff AK, Hensley CB, et al. Rapid redistribution and inhibition of renal sodium transporters during acute pressure natriuresis. Am J Physiol. 1996;270:F1004-F1014.
127. Zhang YB, Magyar CE, Holstein-Rathlou NH, et al. The cytochrome P-450 inhibitor cobalt chloride prevents inhibition of renal Na, K-ATPase and redistribution of apical NHE-3 during acute hypertension. J Am Soc Nephrol. 1998;9:531-537.
128. Dos Santos EA, Dahly-Vernon AJ, Hoagland KM, et al. Inhibition of the formation of EETs and 20-HETE with 1-aminobenzotriazole attenuates pressure natriuresis. Am J Physiol Regul Integr Comp Physiol. 2004;287: R58-R68.
129. Dahly AJ, Hoagland KM, Flasch AK, et al. Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol. 2002;283:R757-R767.
130. Dahly-Vernon AJ, Sharma M, McCarthy ET, et al. Transforming growth factor-beta, 20-HETE interaction, and glomerular injury in Dahl salt-sensitive rats. Hypertension. 2005;45:643-648.
131. Williams JM, Sharma M, Anjaiahh S, et al. Role of endogenous CYP450 metabolites of arachidonic acid in maintaining the glomerular protein permeability barrier. Am J Physiol Renal Physiol. 2007;293: F501-F505.
132. Alonso-Galicia M, Frohlich B, Roman RJ. Induction of P4504A activity improves pressure-natriuresis in Dahl S rats. Hypertension. 1998;31: 232-236.
133. Roman RJ. Abnormal renal hemodynamics and pressure-natriuresis relationship in Dahl salt-sensitive rats. Am J Physiol. 1986;251:F57-F65.
134. Kirchner KA. Increased loop chloride uptake precedes hypertension in Dahl salt-sensitive rats. Am J Physiol. 1992;262:R263-R268.
135. Kirchner KA. Greater loop chloride uptake contributes to blunted pressure natriuresis in Dahl salt sensitive rats. J Am Soc Nephrol. 1990;1: 180-186.
136. Roman RJ, Kaldunski ML. Enhanced chloride reabsorption in the loop of Henle in Dahl salt-sensitive rats. Hypertension. 1991;17: 1018-1024.
137. Hoagland KM, Flasch AK, Dahly-Vernon AJ, et al. Elevated BSC-1 and ROMK expression in Dahl salt-sensitive rat kidneys. Hypertension. 2004;43:860-865.
138. Roman RJ, Ma YH, Frohlich B, et al. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension. 1993;21:985-988.
139. Hoagland KM, Flasch AK, Roman RJ. Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension. 2003;42: 669-673.
140. Gainer JV, Bellamine A, Dawson EP, et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation. 2005;111:63-69.
141. Gainer JV, Lipkowitz MS, Yu C, et al. Association of a CYP4A11 variant and blood pressure in black men. J Am Soc Nephrol. 2008;19:1606-1612.
142. Mayer B, Lieb W, Gotz A, et al. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension. 2005;46:766-771.
143. Mayer B, Lieb W, Gotz A, et al. Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction. J Hypertens. 2006;24:1965-1970.
144. Elijovich F, Laffer CL. The relationship between CYP4A11 and human hypertension. J Hypertens. 2008;26:1712-1714.
145. Fava C, Montagnana M, Almgren P, et al. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension. 2008;52:373-380.
146. Fu Z, Nakayama T, Sato N, et al. Haplotype-based case study of human CYP4A11 gene and cerebral infarction in Japanese subject. Endocrine. 2008;33:215-222.
147. Laffer CL, Gainer JV, Waterman MR, et al. The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension. Hypertension. 2008;51:767-772.
148. Ward NC, Tsai IJ, Barden A, et al. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension. 2008;51: 1393-1398.
149. Fu Z, Nakayama T, Sato N, et al. Haplotype-based case-control study of the human CYP4F2 gene and essential hypertension in Japanese subjects. Hypertens Res. 2008;31:1719-1726.
150. Fu Z, Nakayama T, Sato N, et al. A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men. Am J Hypertens. 2008;21:1216-1223.
151. Liu H, Zhao Y, Nie D, et al. Association of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension. J Am Soc Nephrol. 2008;19:714-721.
152. Liu H, Zhao YY, Gong W, et al. [Correlation analysis and identification of G421C in regulatory region of CYP4F2 gene with essential hypertension]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006;28:143-147.
153. Ding H, Cui G, Zhang L, et al. Association of common variants of CYP4A11 and CYP4F2 with stroke in the Han Chinese population. Pharmacogenet Genomics. 2010;20:187-194.
154. Zordoky BN, El-Kadi AO. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther. 2010;125:446-463.
155. Hermann M, Hellermann JP, Quitzau K, et al. CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease-the ENCORE Trials. Atherosclerosis. 2009;207:476-479.
156. Sugimoto K, Akasaka H, Katsuya T, et al. A polymorphism regulates CYP4A11 transcriptional activity and is associated with hypertension in a Japanese population. Hypertension. 2008;52:1142-1148.
157. Stec DE, Roman RJ, Flasch A, et al. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics. 2007;30: 74-81.
158. Iwai N, Inagami T. Isolation of preferentially expressed genes in the kidneys of hypertensive rats. Hypertension. 1991;17:161-169.
159. Omata K, Abraham NG, Escalante B, et al. Age-related changes in renal cytochrome P-450 arachidonic acid metabolism in spontaneously hypertensive rats. Am J Physiol. 1992;262:F8-F16.
160. Schwartzman ML, da Silva JL, Lin F, et al. Cytochrome P450 4A expression and arachidonic acid omega-hydroxylation in the kidney of the spontaneously hypertensive rat. Nephron. 1996;73:652-663.
161. Wang MH, Zhang F, Marji J, et al. CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR. Am J Physiol Regul Integr Comp Physiol. 2001;280:R255-R261.
162. Escalante B, Sacerdoti D, Davidian MM, et al. Chronic treatment with tin normalizes blood pressure in spontaneously hypertensive rats. Hypertension. 1991;17:776-779.
163. Laniado-Schwartzman M, Abraham NG, Sacerdoti D, et al. Effect of acute and chronic treatment of tin on blood pressure in spontaneously hypertensive rats. Tohoku J Exp Med. 1992;166:85-91.
164. Sacerdoti D, Escalante B, Abraham NG, et al. Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science. 1989;243:388-390.
165. Shatara RK, Quest DW, Wilson TW. Fenofibrate lowers blood pressure in two genetic models of hypertension. Can J Physiol Pharmacol. 2000;78: 367-371.
166. Dunn KM, Renic M, Flasch AK, et al. Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2008;295:H2455-H2465.
167. Hou X, Shen YH, Li C, et al. PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity. Biochem Biophys Res Commun. 2010;394:653-659.
168. Oyekan AO, McAward K, Conetta J, et al. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. Am J Physiol. 1999;276:R766-R775.
169. Quigley R, Chakravarty S, Zhao X, et al. Increased renal proximal convoluted tubule transport contributes to hypertension in Cyp4a14 knockout mice. Nephron Physiol. 2009;113:p23-p28.
170. Nakagawa K, Holla VR, Wei Y, et al. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J Clin Invest. 2006;116:1696-1702.
171. Liu X, Zhao Y, Wang L, et al. Overexpression of cytochrome P450 4F2 in mice increases 20-hydroxyeicosatetraenoic acid production and arterial blood pressure. Kidney Int. 2009;75:1288-1296.
172. Alonso-Galicia M, Falck JR, Reddy KM, et al. 20-HETE agonists and antagonists in the renal circulation. Am J Physiol. 1999;277:F790-F796.
173. Tunctan B, Korkmaz B, Buharalioglu CK, et al. A 20-hydroxyeicosate- traenoic acid agonist, N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine, opposes the fall in blood pressure and vascular reactivity in endotoxin-treated rats. Shock. 2008;30:329-335.
174. Yu M, Cambj-Sapunar L, Kehl F, et al. Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur J Pharmacol. 2004;486: 297-306.
175. Miyata N, Seki T, Tanaka Y, et al. Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4- morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke. J Pharmacol Exp Ther. 2005;314:77-85.
176. Omura T, Tanaka Y, Miyata N, et al. Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stroke. 2006;37:1307-1313.
177. Regner KR, Zuk A, Van Why SK, et al. Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injury. Kidney Int. 2009;75:511-517.